Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC - PubMed
1 Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China. 2 Medical Department, Amoy Diagnostics Co., Ltd., Xiamen, China. 3 Department ..... see more
Thrilled to be a part of this Hackathon. Brainstorming new treatments for #lungcancer Join us if you can help
https://cancerhackerlab.com/linnea-olson/
see more
Linnea olson - CancerHacker Lab
Linnea Olson is a well-known advocate for patients and a pioneer in clinical trials for lung cancer. She was diagnosed with non-small cell lung cancer in April of 2005. Linnea ..... see more
Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China - PubMed
Although the National Comprehensive Cancer Network and the Chinese Society of Clinical Oncology guidelines recommend comprehensive genomic profiling of lung adenocarcinoma, it has not been widely applied in Chinese hospitals. ..... see more
Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from ..... see more
Source : https://www.eurekalert.org/pub_releases/2021-03/esfm-sdt032321.php
Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease - PubMed
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival ..... see more
Targeting KRAS: The Elephant in the Room of Epithelial Cancers - PubMed
Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than ..... see more
STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications - PubMed
Across cancers, STK11 alterations correlated with a poor prognosis regardless of therapy. However, STK11 alterations alone did not associate with inferior immunotherapy outcome in the pan-cancer setting or in NSCLC. ..... see more
Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer [ELCC 2021 Virtual Press Release]
LUGANO, Switzerland; DENVER, CO, USA - Clinical activity with a second drug inhibiting KRAS G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) ..... see more
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
KRAS, an oncogenic driver in lung cancer, is known as an "undruggable" target Different strategies are under investigation to indirectly and directly target KRAS Clinical trials of small-molecule inhibitors report ..... see more
Source : https://www.sciencedirect.com/science/article/pii/S266637912030241X
The Prevalence and Concurrent Pathogenic Mutations of KRAS G12C in Northeast Chinese Non-small-cell Lung Cancer Patients - PubMed
1 Medical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, People's Republic of China. 2 Department of Medical Thoracic ..... see more
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific - PubMed
Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations. Although epidemiological ..... see more
60-Year-Old Professor with Increasing Fatigue
A 60-year-old immunology professor presents complaining of increasing fatigue over the past 3-to-4 months. She had a cough for a couple of weeks that .....
see more
Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.
.....
see more
Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC
Adagrasib (MRTX849) yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C-mutant advanced non-small cell lung cancer, ..... see more
Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
see more
Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer [ELCC 2021 Virtual Press Release]
LUGANO, Switzerland; DENVER, CO, USA - Clinical activity with a second drug inhibiting KRAS G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) ..... see more
Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy - PubMed
Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantification of nucleic acid sequences. We used absolute quantification of mutated v-Ki-ras2 Kirsten rat sarcoma viral ..... see more
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy - PubMed
doi: 10.1158/1535-7163.MCT-20-0462. Online ahead of print. 1 Research, Mirati Therapeutics (United States). 2 cancer center, New York University School of Medicine. 3 Research - Biology, Mirati Therapeutics (United States). 4 ..... see more
KRAS G12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma - PubMed
1 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Pulmonary Medicine, Berlin, Germany. 2 Helios ..... see more
The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
Peter Radeczky, 1, 2 Zsolt Megyesfalvi, 1, 2, 3 Viktoria Laszlo, 2, 3 Janos Fillinger, 1, 2 Judit Moldvay, 2, 4 Erzsebet Raso, 5 Erzsebet Schlegl, 2 Tamas Barbai, 5 ..... see more
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947398/
"Asked about adoption in the clinic if the drug gains approval, Li said the first step will be to start testing all NSCLC patients for KRAS mutations."
.....
see more
KRAS Inhibitor Continues to Impress in NSCLC
More than a third of patients with pretreated non-small cell lung cancer (NSCLC) and a KRAS G12C mutation responded to the investigational agent sotorasib, findings from a phase II study ..... see more
Source : https://www.medpagetoday.com/meetingcoverage/iaslc/90989
This is scary.
“More than one in 10 patients with lung cancer do not know what type of tumour they have.”
Educated patients .....
see more
More Than One in 10 Patients With Lung Cancer Do Not Know What Type They Have [ESMO Press Release]
LUGANO, Switzerland; DENVER, CO, USA - More than one in 10 patients with lung cancer do not know what type of tumour they have, according to data from a 17-country ..... see more